Abstract

Tuberous sclerosis complex 1 (TSC1) and TSC2 tumor suppressor proteins have been shown to negatively regulate cell growth through inhibition of the mammalian target of rapamycin (mTOR) pathway. Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that plays a critical role in integrin signaling. Here we identify a novel interaction between FAK and TSC2 and show that TSC2 is phosphorylated by FAK. Furthermore, we show that overexpression of FAK kinase dead mutant inhibits the phosphorylation of ribosomal S6 kinase (S6K) and eukaryotic initiation factor 4E-binding protein-1, two key mTOR (mammalian target of rapamycin) downstream targets, and negatively regulates the cell size and that FAK regulation of S6K phosphorylation is through TSC2. Finally, we provide data that FAK plays a positive role in cell adhesion-induced S6K phosphorylation, whereas TSC2 is required for cell suspension-induced S6K inactivation. Together, these results suggest that FAK might regulate S6K activation and cell size through its interaction with and phosphorylation of TSC2 and also provide a previously unappreciated role of TSC2 in the regulation of mTOR signaling by cell adhesion.

Highlights

  • Can form a physical and functional complex in vivo [7, 8]

  • We demonstrate that overexpression of Focal adhesion kinase (FAK) kinase dead mutant inhibits the phosphorylation of S6 kinase (S6K) and 4E binding protein-1 (4EBP-1) and negatively regulates the cell size and that FAK regulation of S6K phosphorylation is through TSC2

  • Overexpression of FAK kinase dead mutant (FAK kd) mutant inhibits the phosphorylation of S6K and 4EBP-1 and decreases cell size in 293T cells

Read more

Summary

Introduction

Can form a physical and functional complex in vivo [7, 8]. TSC1 has no known enzymatic activity, TSC2 contains a carboxyl-terminal GAP domain for the small G protein Rheb. The vector encoding GST-tagged TSC2 and HA-tagged FAK or HA empty vector were co-transfected into 293T cells followed by immunoprecipitation by anti-HA antibody.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call